Ernexa Therapeutics Inc. - 10-Q Filing
Ernexa Therapeutics filed its Q1 2026 10-Q report with the SEC, disclosing financial results for the quarter ended March 31, 2026. The filing outlines operating expenses including research and development costs of $4.8 million and general administrative expenses of $2.5 million during the period. As a clinical-stage biopharmaceutical company, it reported no revenue from operations.
Tickers: $ERNA